YU Wing Tak Wendy 4

What Happened YU Wing Tak Wendy (Wendy Yu), a director of Niagen Bioscience, was granted a derivative equity award on June 24, 2026 covering 31,746 shares. The Form 4 reports an acquisition price of $0.00 (derivative), so no cash was paid at grant and the filing shows a $0 reported value for the transaction.

Key Details

• Transaction date: 2026-06-24; Form 4 filed: 2026-06-26 (filed within the typical two-business-day window).
• Amount granted: 31,746 derivative shares; reported price: $0.00.
• Vesting: 100% vests on June 24, 2027 (per footnote).
• Shares owned after transaction: not specified in the provided summary of the filing.
• Filing type: Grant / award (derivative). No sale or open-market purchase reported.

Context This was an equity award (derivative/option-style grant) rather than an immediate purchase or sale of stock. Such grants are common for board compensation and do not, by themselves, indicate buying or selling sentiment until options are exercised or shares are sold. The Form 4 does not disclose additional terms (e.g., strike price or post-vesting restrictions) beyond the 100% vesting date.